DMA officials confirmed what we’ve heard from our members thus far. Many oncology and rheumatology drugs, vaccines, and long-term reversible contraceptives (to name a few) are cited as costing physicians significantly more than they are being reimbursed by the program. And as more time passes, more drugs move into this “underwater” status. DMA acknowledged this can become an access to care issue, and expressed willingness to work to reduce the gap in reimbursement.
As the NCMS continues to address this matter, it would be helpful to get a fuller understanding of if – and how dramatically – your practice is affected by these below cost drug reimbursements. Please post your comments at the end of this article, and watch the Bulletin for updates as our work on this issue continues.